30 closest matches · ranked by relevance
Tumor Induced Osteomalacia (TIO) · Epidermal Nevus Syndrome (ENS)
Primary: Percentage of Participants Achieving Mean Serum Phosphorus Levels Above 2.5 mg/dL at the Mid-Point of the Dose Intervals Between Baseline and Week 24 — 50.0 percentage…
Osteomalacia
Primary: Number of Participants With Positive Localization of Phosphaturic Mesenchymal Tumors (PMTs) — 15 Participants
Rothmund-Thomson Syndrome
Primary: Bone Density (Low Areal Bone Mineral Density (aBMD)) — -1.3; -0.9; -2.4; -1.2 z-score
Osteogenesis Imperfecta
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 2; 4; 2; 1 Participants
Menopause · Fracture · Osteoporosis
Primary: Change in Lumbar Spine Bone Density by Dual Energy X-ray Absorptiometry (DXA) — 10.8 percentage of BMD change
Adult Idiopathic Generalized Osteoporosis
Primary: Change in Lumbar Spine Bone Mineral Density (LS-BMD) on Active Medication — 10.1; 4.1 percentage of change
Autosomal Dominant Osteopetrosis Type 2
Primary: Changes in Bone Resorption Markers From Baseline to 14 Weeks. — 2.2; -2.1 percentage of change
Osteoporosis · Humoral Hypercalcemia of Malignancy · Hyperparathyroidism
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 2; 2 participants
Osteogenesis Imperfecta
Primary: Spine Bone Mineral Density (BMD) — 6.1; 2.8 percentage of change in g/cm2
Kidney Failure, Chronic
Primary: Change in Quantitative Computed Tomography (QCT) Bone Mineral Density of the Hip — -10.71; 5.72; -3.52; .2 g/cm^3 — p=.443
Fibrodysplasia Ossificans Progressiva
Primary: Annualized New Heterotopic Ossification (HO) — 9427.1; 23720.2 cubic millimeters (mm^3)
Fibrodysplasia Ossificans Progressiva
Primary: Parts A and B: Percentage of Flare-ups With No New Heterotopic Ossification (HO) at Week 12 — 64.3; 72.5 percentage of flare-ups
Lymphangioleiomyomatosis · Lymphangiomyomas · Pleural Effusions
Primary: Number of Participants With a Reduction in Total Tumor Volume of at Least 20%. — 0 Participants
Hypophosphatemic Rickets, X Linked Dominant
Primary: Area Under the Curve for FGF23 — 3172.34; 3215.34 pg/ml*hr
Fibrodysplasia Ossificans Progressiva
Primary: Percentage of Responders at Week 6 — 100; 88.9; 88.9 percentage of subjects — p=0.1664
Parathyroid Disease
Primary: Detection Rate of Parathyroid Adenomas of Anti-3-[18F]FACBC Modality — 80 percentage of adenomas detected
Secondary Hyperparathyroidism
Primary: The Level of Activated Vitamin D (1,25-dihydroxyvitamin D) After Parathyroid Hormone Infusion at Baseline, 4 and 8 Hours — 40.6; 46.2; 39.8; 58.8 pg/ml — p=0.1
Dent Disease
Primary: Change in Urine Total Protein — 1681; 59 mg/day
Secondary Hyperparathyroidism · Chronic Kidney Disease
Primary: Percent of Patients Achieving Parathyroid Hormone Target ≤ 300 — 21 percentage of subjects meeting target — p=< 0.05
Differentiated Thyroid Cancer · Osteoporosis
Primary: Percent Change of Bone Mineral Density in Lumbar and Hip — 3.0; 3.2; 3.8; 5.1 percentage change
Rheumatoid Arthritis · Crohn's Disease
Primary: Intestinal Absorption of Calcium
Giant Cell Tumors
Primary: Number of Participants According to the Management Plan in Patients With Diffuse TGCT (d-TGCT) — 94; NA; NA; NA Participants
Bone Cancer · Chondrosarcoma · Ewing's Sarcoma
Primary: T2* Relaxation Time of Bone Sarcomas and Osteomyelitis Subjects — 7.3; 7.7 milliseconds
Fibrous Dysplasia Of Bone
Primary: Proportion of Participants With Serum Phosphate Levels Within the Target Range at Week 48 — 1 Proportion of participant
Desmoid Tumor
Primary: Immunohistochemical Immunoreactive Score Results After 4 Weeks of Sirolimus Compared to Control Specimens — 5.22; 7.44; 4.47; 9.39 score on a scale — p=0.63
Osteoporosis
Primary: Changes in T-cell Activation Measured by Flow Cytometry, Specifically the Percentage of CD3+CD69+ T-cells — 3.6; 1.8 percentage of CD3 positive cells
Osteoporosis
Primary: Percentage Change in the Bone Formation Marker N-terminal Propeptides of Human Procollagen Type I (P1NP) From Baseline to End of Trial — 446.1; -6.2 percent change…
Kidney Disease
Primary: Percentage Changes in Fibroblast Growth Factor-23 (FGF-23) Levels — -0.35; 0.25; 0.00; -0.02 percentage of change from baseline
Osteopetrosis
Primary: Number of Participants With Treatment Related Adverse Events CTCAE v4.0 Grade 3 or Higher — 0 Participants
Postmenopausal Osteoporosis · Osteoporosis
Primary: Changes in Indices of Bone Turnover — 4418; 3696; 956; 822 months*(ng/ml - baseline ng/ml)